Periodontal-induced chronic inflammation triggers macrophage secretion of Ccl12 to inhibit fibroblast-mediated cardiac wound healing

Kristine Y. DeLeon-Pennell,1,2 Rugmani Padmanabhan Iyer,2 Osasere K. Ero,2 Courtney A. Cates,2 Elizabeth R. Flynn,2 Presley L. Cannon,2 Mira Jung,2 De’Aries Shannon,2 Michael R. Garrett,3 William Buchanan,4 Michael E. Hall,2,5 Yonggang Ma,2 and Merry L. Lindsey1,2

1Research Service, G.V. (Sonny) Montgomery Veterans Affairs Medical Center, Jackson, Mississippi, USA. 2Mississippi Center for Heart Research, Department of Physiology and Biophysics, 3Department of Pharmacology and Toxicology, 4Department of Periodontics and Preventive Science, and 5Division of Cardiology, University of Mississippi Medical Center, Jackson, Mississippi, USA.

Introduction

Periodontal disease (PD) is associated with adverse wound healing in response to injury across organ systems, including poor cardiac responses to myocardial infarction (MI) (1–6). MI incidence correlates with the number of pockets > 4 mm deep, bleeding sites after probing, and severity of tooth loss, even after adjustment for known cardiovascular risk factors (e.g., smoking, diabetes, or hypertension) (4). Antibodies against the periodontal pathogen Porphyromonas gingivalis are also elevated in MI patients (4), and heart-failure patients exhibit increased bone turnover markers in circulation and a more advanced PD phenotype compared with healthy control patients (6). In addition, severe periodontitis is more prevalent among post-MI heart-failure patients than dilated cardiomyopathy–induced heart-failure patients (5). PD is caused by chronic inflammation of tissues surrounding the teeth, in response to bacterial biofilm accumulation (7). Bacterial products, especially endotoxins, are key drivers of inflammation and PD development (8). It is hypothesized that the link between PD and cardiovascular disease (CVD) is due to chronic inflammatory mechanisms initiated by the bacteria products present within periodontal lesions (9). While the oral health and CVD epidemiological correlation is quite strong, the mechanistic link between oral health and MI response is not fully understood.

Porphyromonas gingivalis is one of the most frequent PD pathogens detected in the gums and circulation of patients with PD (10). Previously, we showed subseptic concentrations (0.8 μg/g body weight/day) of Porphyromonas gingivalis lipopolysaccharide (LPS) exacerbated infarct expression of the proinflammatory cytokine Ccl12. Ccl12 prevented initiation of the reparative response by prolonging inflammation and inhibiting fibroblast conversion to myofibroblasts, resulting in diminished scar formation. Macrophage secretion of Ccl12 directly impaired fibronectin and collagen deposition and indirectly stimulated collagen degradation through upregulation of matrix metalloproteinase-2. In post-MI patients, circulating LPS levels strongly associated with the Ccl12 homologue monocyte chemotactic protein 1 (MCP-1). Patients with LPS levels ≥ 1 endotoxin units (EU)/ml (subseptic endotoxemia) at the time of hospitalization had increased end diastolic and systolic dimensions compared with post-MI patients with < 1 EU/ml, indicating that low yet pathological concentrations of circulating LPS adversely impact post-MI left ventricle (LV) remodeling by increasing MCP-1. Our study provides the first evidence to our knowledge that chronic inflammation inhibits reparative fibroblast activation and generates an unfavorable cardiac–healing environment through Ccl12-dependent mechanisms.
Porphyromonas gingivalis lipopolysaccharide (LPS) accelerated macrophage infiltration and increased cardiac rupture after MI in mice, suggesting PD-induced chronic inflammation may alter scar formation by altering the macrophage population (11).

Fibroblasts are the primary source of extracellular matrix (ECM) in the myocardium. A balanced turnover of ECM through matrix metalloproteinase–mediated (MMP-mediated) degradation and reparative fibroblast ECM synthesis is critical for adequate post-MI scar formation (12). Macrophages regulate both sides of the degradation and synthesis equation. Secretion of proinflammatory molecules such as TNF-α and IL-1β stimulates ECM degradation and tissue clearance by promoting MMP production, while secretion of antiinflammatory molecules such as TGF-β1 promote ECM synthesis and scar deposition (13). Despite our knowledge that macrophages regulate ECM turnover, little is known about the mechanisms behind macrophage activation as a means to regulate scar formation. The goal of the present study was to use a multidimensional systems biology approach to elucidate the molecular basis for impaired cardiac wound healing in the setting of periodontal-induced chronic inflammation.

**Results**

**Chronic inflammation prolonged proinflammatory macrophage infiltration after MI.** To dissect macrophage regulation of post-MI scar formation, we assessed day 7 (d7) post-MI infarcts from LPS preexposed mice (LPS+MI), compared with both MI positive controls and no-MI negative controls (d0). At d7 after MI, macrophages are the predominant inflammatory cell type present in the left ventricle (LV) infarct, with ~1.5 × 10^6 cells/mg infarct (14, 15). LPS+MI decreased total leukocyte count (CD11b+ cells) and macrophage numbers (Mac3+ and F4/80+ cells) in the infarct at d7 after MI, detected by immunofluorescent staining (Figure 1, A–D), cell counts (Figure 1E), and flow cytometry (Figure 1F). Previously, we have shown LPS exposure increased macrophage infiltration at d1 after MI when compared with controls (11). The data indicate that LPS treatment accelerated the macrophage influx timeline, resulting in a more rapid peak and efflux.

In addition to fewer macrophages within the infarct, there was also a decrease in CD206+ cells (Figure 1G). This decline was predominantly due to a drop in the reparative M2 macrophage population (F4/80+CD206+; Figure 1H). By d7 after MI, proinflammatory factors subside to facilitate collagen deposition and reparative fibroblast activation (16). In MI controls, 70% ± 3% of macrophages at d7 after MI were reparative M2 macrophages (Figure 1H, second quadrant), consistent with previous findings (14, 17). In contrast, only 54% ± 4% of LPS+MI macrophages were reparative M2 macrophages (P < 0.05). M1 macrophage numbers were not changed, resulting in an increased M1/M2 ratio (Figure 1H).

Proinflammatory M1 marker gene expression for Ccl3, IL-1β, and TNF-α, but not IL-6, were higher in macrophages isolated from LPS+MI mice compared with d7 post-MI controls (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.94207DS1). While the M2 marker CD206 was significantly lower at the protein level, no differences were observed in gene levels of any of the M2 markers evaluated (Arg1, CD206, Fizz, or Ym1). Although d7 post-MI macrophage numbers were decreased with LPS exposure, the net phenotype remained proinflammatory, leading to excessive and prolonged myocardial injury.

A multiomics approach revealed monocyte chemotactic protein-5 (MCP-5; Ccl12) as a potent proinflammatory MI macrophage marker. By hierarchal clustering of 168 inflammatory and ECM genes (Supplemental Table 1), the top 25 ranked differences in the LV infarct were linked to macrophage biology and proinflammation. Of these differences, 23 genes were upregulated and 2 downregulated in the LPS+MI infarct (Supplemental Figure 2A), compared with MI controls. Integrated pathway analysis revealed the main targeted pathways in the LPS+MI LV involved leukocyte extravasation (Supplemental Figure 2B). Changes in leukocyte kinetics would tip the balance toward a poor wound healing environment. The proinflammatory cytokine, Ccl12, was identified as the top feature exacerbated at d7 in the LPS+MI LV, by both volcano plot and causal network analyses (Supplemental Figure 2, C and D). In our previous study, we identified MCP-1 and -3 as being significantly elevated in LPS+MI mice compared with MI controls at d1 after MI (11). By d7, both MCP-1 and -3 were no longer significantly elevated in our LPS+MI mice compared with MI controls (Supplemental Table 1). Our results suggest that MCP-1 and -3 are fundamental during the early but not later post-MI phase and explain why we had an acceleration of the macrophage infiltration timeline with chronic LPS exposure. In the current study, Ccl12 is elevated at d1 in the LPS+MI group, and this elevation persisted through d7.
Ccl12 is an M1 marker highly expressed by macrophages and is associated with monocyte-derived macrophage and fibroblast recruitment (18). Ccl12 mRNA increased 150-fold at d5 and d7 in the infarct region, compared with d0, and the increase in Ccl12 mirrored the influx of monocyte-derived macrophages into the infarct area (Figure 2A). Increased Ccl12 was accelerated and doubled in the LPS+MI mice. Previously, we showed macrophage infiltration began earlier with LPS exposure (11). Consistent with the past report, Ccl12 spiked in the LPS+MI group at d1 after MI. The source of Ccl12 was the macrophage, as Ccl12 mRNA expression was 2-fold elevated, and protein secretion was 3-fold elevated, in macrophages isolated from the d7 infarct region (Figure 2, B and C). This was unexpected because total macrophage numbers were decreased in the LPS+MI group at d7 after MI, compared with the MI group. Ccl2, a homologue of Ccl12, was not significantly different in macrophages isolated from the infarct of d7 post-MI LV controls compared with the LPS+MI group. Since macrophages are known to regulate ECM deposition and scar formation (12, 17, 19), we hypothesized that chronic inflammation may prolong M1 macrophage polarization to regulate fibroblast function through increased secretion of Ccl12. We provide here the first evidence to our knowledge that chronic inflammation exacerbated macrophage secretion of Ccl12.

Chronic inflammation reduced infarct strength by altering ECM composition to destabilize the infarct region. Ccl12 directly and negatively linked with fibronectin and indirectly and positively linked with collagen degradation through MMP-2, elucidated by causal network analysis (Supplemental Figure 2D). Fibronectin and collagen are key ECM proteins that dictate the infarct scar formation (12, 20). Post-MI, full-length...
fibronectin, collagen I, and collagen III each increased at least 10-fold at d7 post-MI compared with no-MI controls (Figure 3, A–C). LPS+MI decreased the MI-stimulated increase in full-length fibronectin and collagen III protein more than 2-fold without a concomitant fall in mRNA levels (Supplemental Table 1), demonstrating impaired ECM synthesis or deposition. Accelerated collagen I turnover, as evidenced by enhanced collagen fragmentation, was significantly higher in LPS+MI LV compared with MI controls (Figure 3B).

MMP-2 was the key regulator for the increased collagen turnover in the LPS+MI LV, as MMP-2 was the only one of 12 MMPs measured that was significantly higher and negatively correlated with decreased wall thickness in LPS+MI LV (Supplemental Table 1 and Figure 3D). In addition to ECM synthesis and deposition, ECM cross-linking is a necessary component to generate scars of sufficient strength. Lysyl oxidase (LOX), the major collagen cross-linking enzyme, increases during the MI maturation phase (21, 22). LPS+MI reduced LOX at d7 after MI compared with MI controls (Figure 4A). After MI, fibroblasts differentiate into myofibroblasts and actively produce ECM. Myofibroblasts are more contractile and have increased potential for ECM synthesis than fibroblasts, enabling repair. The myofibroblasts marker, α–smooth muscle actin (αSMA), was significantly decreased in the infarct area of LPS+MI mice (Figure 4B), indicating diminished differentiation capacity.

Impaired ECM synthesis and insufficient cross-linking can increase wall stress, initiating excessive infarct expansion and increasing susceptibility to rupture (23). Chronic inflammation accelerated the timing and increased the incidence of cardiac rupture in the current cohort of mice (Figure 5, A and B), consistent with previous findings (11). Post-MI cardiac dysfunction was exacerbated by chronic inflammation, as indicated by increased infarct wall thinning and decreased LV remodeling index (Table 1). Early after MI, the infarct is less extensible in both the circumferential and longitudinal directions (24). LPS+MI exacerbated myocardial fiber rearrangement, resulting in decreased overall radial strain, systolic radial strain, and systolic longitudinal strain (Figure 5, C–F). Impaired strain reflects increased myocardial wall stress, with concomitant decreased cardiac physiology and increased rupture (25). These results implicate Ccl12 as a possible mediator of adverse cardiac wound healing during chronic inflammation by interfering with multiple scar formation components.

Macrophage secretion of Ccl12 regulated ECM gene expression, reparative fibroblast activation, and proliferation. To determine the mechanisms whereby macrophage secretion of Ccl12 was responsible for decreased ECM deposition, macrophages were isolated from the MI and LPS+MI infarct regions and cultured for 18 hours to collect the secretome. Cells underwent a washing step before culture to remove any residual LPS left from in vivo exposure in order to ensure effects observed were due to MI-stimulated macrophage secretion. Fibroblasts isolated from control unoperated LVs and exposed to the secretomes of macrophages isolated from d7 LPS+MI infarcts were more proliferative than fibroblasts stimulated with the MI macrophage secretome (Figure 6, A and B). No differences were observed in migration between LPS+MI and MI macrophage secretome–stimulated fibroblasts.

Ccl12 inhibition (Ccl12i) decreased proliferation and increased migration in fibroblasts stimulated with the secretome of macrophages isolated from the LPS+MI infarct, indicating the secretome effect was Ccl12 mediated. When Ccl12 signaling was blocked, proliferation decreased with a concomitant rise in migration. LPS alone did not explain the in vivo fibroblast phenotype, as cardiac fibroblasts stimulated in vitro

**Figure 2. Chronic inflammation enhanced macrophage secretion of Ccl12, a proinflammatory M1 macrophage marker.** At d7 after myocardial infarction (MI), Ccl12 expression was significantly higher in lipopolysaccharide (LPS) preexposed mice (LPS+MI) in both (A) infarct tissue (n = 6/group [3M, 3F]; MI = 5.2 ± 0.1 months; LPS+MI = 6.0 ± 0.1 months) and (B) isolated macrophages (n = 6/group [3M, 3F]; MI = 4.0 ± 0.1 months; LPS+MI = 4.4 ± 0.1 months). (C) By ELISA of the post-MI macrophage secretome, Ccl12 secretion increased 3-fold in LPS+MI macrophages compared with MI macrophages. n = 8/group (4M, 4F); MI = 3.9 ± 0.3 months; LPS+MI = 4.5 ± 0.1 months. Data is shown as box and whisker plots with mean ± minimum/maximum. Time course was analyzed by one-way ANOVA, followed by the Student Newman-Keuls. For two group comparisons, the nonparametric Wilcoxon rank sum test was used. *P < 0.05 vs. d0; †P < 0.05 vs. WT MI.
with the same nonseptic concentrations of LPS demonstrated no direct effect on proliferation or F-actin formation (Supplemental Figure 3). These results are consistent with studies in human gingival and small intestinal lamina propria fibroblasts (26–28). LPS, therefore, was not directly responsible for the in vivo changes in fibroblast function; this effect was via LPS-induced macrophage secretion of Ccl12.

Fibroblasts isolated from control unoperated LVs and stimulated with LPS+MI macrophage secretome exhibited reduced mRNA expression of collagen I, TGFβ1, and αSMA (Figure 6B). Ccl12i restored αSMA gene expression, unmasking the importance of Ccl12 in regulating fibroblast differentiation. The effect was not autocrine because fibroblasts expressed 20-fold lower Ccl12 at all post-MI times examined, compared with macrophage contributions, and therefore the fibroblast was not a relevant Ccl12 source (Supplemental Figure 4A). Gene levels of connective tissue growth factor (Ctgf), collagen III, and fibronectin were not significantly different between LPS+MI and MI controls (Supplemental Figure 4B). Proinflammatory macrophage secretion of Ccl12, therefore, directly regulated post-MI fibroblast activation and ECM deposition.

The secretome of macrophages isolated from d7 LPS+MI infarcts inhibited fibroblast secretion of pro–collagen I and fibronectin protein, demonstrated by immunoblot analysis of fibroblast-conditioned media (Figure 6C and Supplemental Figure 4C). Ccl12i partially restored collagen I but not fibronectin protein in LPS+MI macrophage secretome–exposed fibroblasts. Our results indicate that fibroblasts within a proinflammatory environment further impair wound healing by failing to undergo myofibroblast activation. Of the secretome constituents, our data identified Ccl12 as the contributor to adverse remodeling by increasing fibroblast proliferation and decreasing fibroblast migration and activation to impair collagen production.
Figure 4. Chronic inflammation decreased fibroblast differentiation and increased proliferation at d7 after myocardial infarction (MI). (A) Representative immunoblot. n = 6/group (3M, 3F); MI = 5.1 ± 0.1 months; LPS+MI = 5.9 ± 0.1 months. The collagen cross-linking enzyme, lysyl oxidase (LOX), was lower in infarcts of LPS+MI mice at d7 after MI compared with MI controls. (B) By immunofluorescence, the percent area stained positive for α-smooth muscle actin (α-SMA) was reduced in the LPS+MI infarcts at d7 after MI. Scale bar: 60 μm. n = 6/group (3M, 3F); MI = 4.8 ± 0.1 months; LPS+MI = 5.2 ± 0.1 months. By d7 after MI, fibroblasts typically differentiate into the reparative myofibroblast phenotype to increase ECM production. Our data indicate chronic inflammation impaired wound healing by inhibiting myofibroblast activation. Data is shown as box and whisker plots with mean ± minimum/maximum; LOX was analyzed by one-way ANOVA, followed by the Student Newman-Keuls, and α-SMA was analyzed by nonparametric Wilcoxon rank sum test. *P < 0.05 vs. d0; †P < 0.05 vs. WT MI.

Ccl12 mimicked effects of chronic inflammation on fibroblast ECM gene expression, reparative fibroblast activation, and proliferation. To determine how the effects of chronic inflammation on post-MI wound healing were directly due to elevated Ccl12 levels, no MI cardiac fibroblasts were stimulated with Ccl12 recombinant protein. To assess the Ccl12 signaling pathway, Ccr2— the only known Ccl12 receptor — was inhibited to determine whether Ccl12 actions were dependent on Ccr2 activation (29). Ccr2 inhibition (Ccr2i) totally obliterated fibroblast migration, which was predictable, as Ccr2 is vital for cell migration (18, 30). Fibroblasts stimulated with Ccl12 were proliferative (BrdU-positive) independent of Ccr2, confirming that Ccl12 can directly stimulate fibroblast proliferation through Ccr2-independent signaling (Figure 7A).

Providing additional proof that Ccl12 is responsible for LPS+MI effects on fibroblast dysfunction, Ccl12 decreased fibroblast expression of collagen I, fibronectin, TGFβ1, and α-SMA (Figure 7B). Stimulating fibroblasts with Ccl12 did not directly affect collagen III or Ctgf (Supplemental Figure 4D). This is consistent with what has been observed with the Ccl12 human isoform, hMCP-1, as stimulation of human fibroblasts from multiple sources (fetal or adult lung or adipose tissue) with hMCP-1 in vitro inhibits collagen expression and decreases α-SMA expression (31). While the effects of Ccl12 on proliferation and migration were independent of Ccr2, Ccr2i restored effects on collagen I, fibronectin, TGFβ1, and α-SMA protein expression. This suggests that Ccl12 actions are both dependent and independent of Ccr2 engagement.

To dissect Ccl12 effects in vivo, mice were infused with either recombinant Ccl12 or a Ccl12 blocking antibody (Ccl12i) at the time of MI surgery by s.c. osmotic minipump placement. Similar to what was observed in LPS+MI mice, increasing Ccl12 levels increased LV wall thinning and incidence of cardiac rupture (Table 1 and Figure 7C). Bound Ccl12 (25-kDa band) increased 2-fold with Ccl12i infusion, indicating the blocking antibody was successfully binding to Ccl12 and, thus, inhibiting its biological activity (Figure 7D). Collagen I fragmentation and active MMP-2 levels were also enhanced with Ccl12 infusion compared with MI controls (Figure 7, E and F). Administration of Ccl12i attenuated this affect and provided further evidence that Ccl12 is a key regulator of adverse post-MI wound healing. The IgG control antibody group had no significant differences in cardiac physiology (Table 1), bound Ccl12 levels, collagen fragmentation, or active MMP-2 levels (Figure 7, D–F) compared with the MI nonexposed controls. Our data present a crucial role for macrophage secretion of Ccl12 in the setting of chronic inflammation to stimulate fibroblast dysfunction.

In humans, elevated subseptic levels of circulating LPS in post-MI patients linked to circulating hMCP-1 concentrations and increased LV dilation. Humans express Ccl2 (MCP-1) but not Ccl12 (MCP-5), while mice have both homologues of hMCP-1: mCcl2 (MCP-1) and mCcl12 (MCP-5). Protein alignment showed mCcl2 was 75% homologous (Bit Score = 114, E-value = 1 × 10−38) to hMCP-1, while mCcl12 was 84% homologous (Bit score = 138, E-value = 6 × 10−48) (Figure 8A). The differences in protein sequence resulted in structural changes in mCcl2 that are absent in mCcl12 and hMCP-1 (Figure 8B). While sequence homology is high for both isoforms, hMCP-1 and mCcl12 contain a β-strand at residue 20 that is absent in mCcl2, resulting in changes in binding efficiency and, thus, protein function (32–34). Mouse Ccl12, therefore, is closer in homology and structure to hMCP-1. Because of this, mouse Ccl12 is also termed MCP-1–related chemokine.

In patients with acute coronary syndrome, high plasma hMCP-1 concentrations (>238 pg/ml) increased the risk of death and recurrent ischemic events by 2-fold, independent of standard risk predictors (35). To determine if chronic inflammation could be linked to elevated hMCP-1 levels and clinical indices of adverse
Table 1. Chronic inflammation exacerbates left ventricular dysfunction after MI

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 38)</th>
<th>LPS exposed (n = 27)</th>
<th>Ccl12 recombinant (n = 4)</th>
<th>Ccl12i (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>d0</td>
<td>d7</td>
<td>d0</td>
<td>d7</td>
</tr>
<tr>
<td>Age (months)</td>
<td>4.6 ± 0.1</td>
<td>4.7 ± 0.1</td>
<td>4.3 ± 0.1</td>
<td>5.3 ± 0.1</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>472 ± 6</td>
<td>490 ± 9</td>
<td>466 ± 8</td>
<td>482 ± 13</td>
</tr>
<tr>
<td>Infarct area (%)</td>
<td>N/A</td>
<td>42 ± 5</td>
<td>N/A</td>
<td>43 ± 7</td>
</tr>
<tr>
<td>Wall thickness diastole (mm)</td>
<td>0.78 ± 0.02</td>
<td>0.60 ± 0.03</td>
<td>0.75 ± 0.02</td>
<td>0.45 ± 0.02</td>
</tr>
<tr>
<td>EDD (mm)</td>
<td>3.60 ± 0.05</td>
<td>5.40 ± 0.16</td>
<td>3.53 ± 0.05</td>
<td>5.30 ± 0.11</td>
</tr>
<tr>
<td>ESD (mm)</td>
<td>2.20 ± 0.05</td>
<td>5.04 ± 0.16</td>
<td>2.24 ± 0.06</td>
<td>4.94 ± 0.13</td>
</tr>
<tr>
<td>FS (%)</td>
<td>38 ± 1</td>
<td>7 ± 1</td>
<td>34 ± 1</td>
<td>5 ± 1</td>
</tr>
<tr>
<td>EDV (μl)</td>
<td>55 ± 2</td>
<td>134 ± 7</td>
<td>122 ± 8</td>
<td>140 ± 25</td>
</tr>
<tr>
<td>ESV (μl)</td>
<td>19 ± 1</td>
<td>118 ± 7</td>
<td>107 ± 8</td>
<td>129 ± 23</td>
</tr>
<tr>
<td>EF (%)</td>
<td>66 ± 1</td>
<td>13 ± 1</td>
<td>60 ± 3</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>LVRI (mg/μl)</td>
<td>N/A</td>
<td>0.86 ± 0.06</td>
<td>N/A</td>
<td>0.70 ± 0.03</td>
</tr>
</tbody>
</table>

The d0 and d7 MI values for each group are from serial images of the same mice. Because physiological measurements showed no significant differences between nonexposed controls and IgG controls, echocardiography data for these two sets were combined. Data represent mean ± SEM. Controls, nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume). A nonexposed and IgG mice; Ccl12i, Ccl12 blocking antibody; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVRI, left ventricular remodeling index (LVRI = LV mass/end diastolic volume).

remodeling, we measured circulating plasma endotoxin levels in post-MI patients (n = 97; age, median 58 years and range 33–86 years; 38% women; 48% African American), using plasma collected during hospitalization and compared with echocardiography and clinical characteristics (Table 2). The average time for sample collection was 22 ± 12 hours after presentation. There was no significant difference in sample collection times between the high and low endotoxin groups (P = 0.75). The majority of MI patients underwent percutaneous coronary intervention (PCI; 78/97; 81%). The rest were treated either with a thrombolytic (2/97; 2%), a combination of anticoagulant and antiplatelet (15/97; 15%), or coronary bypass surgery (2/97; 2%). There were no significant differences in interventions between groups (P = 0.94). Out of the 97 MI patients enrolled, 34 had a history of diabetes (29 in low [37%] and 5 in high [38%] endotoxin groups; P = 0.96).

LPS levels in plasma from healthy donors have a range of < 1 EU/ml. In periodontal patients, LPS circulating levels can range from 1–4 EU/ml (10). MI patients with significantly elevated nonseptic endotoxemia (>1 EU/ml) had higher end systolic and diastolic LV internal diameters and higher circulating hMCP-1 (Table 2 and Figure 8C). There were no signs of acute complications (e.g., respiratory tract or urinary tract infection, or infection due to indwelling line) in any of the patients enrolled. Age, sex, BMI, systolic blood pressure, smoking history, diabetes history, and troponin, triglyceride, and cholesterol levels did not explain the effect, as each of these variables was not significantly different between groups. Elevated endotoxin levels significantly correlated with increased circulating hMCP-1 levels (Figure 8D). In addition, MMP-12, a macrophage marker, correlated with increased left ventricular internal systolic diameter (LVISD), demonstrating the impact of macrophage-mediated inflammation on cardiac physiology. For 83 patients (86%), this was their first MI. Of the 14 patients with a previous MI, only 1 was in the high-endotoxin group. Removal of these 14 samples did not affect significance for MCP-1 levels (P = 0.01), LVISD (P = 0.005), LVDD (P = 0.004), or correlation of endotoxin to MCP-1 (r = 0.23, P = 0.04).

Discussion

In this study, we combined genomic, proteomic, biochemical, and pathophysiological evaluations in mice and human MI subjects to elucidate the role of PD-induced chronic inflammation on cardiac wound healing after MI. Our study is the first to our knowledge to reveal that chronic inflammation increases macrophage secretion of Ccl12 to inhibit reparative fibroblast activation and ECM deposition (Figure 9). This resulted in decreased cardiac function and increased cardiac rupture, revealing that fibroblast activation is a critical step for stable scar formation.
Approximately 45% of the population in the US and Europe have been diagnosed with PD (36). Chronic inflammation associates with increased fibrosis across a variety of organs, including the lung and intestine (37, 38). When superimposed on MI, chronic inflammation prolongs wound healing and generates a potentially inadequate scar. Our findings are consistent with studies in early-stage diabetic hearts, where cardiac fibroblasts were highly proliferative and proinflammatory, resulting in compromised wound healing and increased LV dilation (39). Understanding how chronic inflammation alters cardiac wound healing provides insight into how to limit post-MI progression to congestive heart failure.

Activated fibroblasts are the primary source of ECM proteins that comprise the infarct scar, and dysregulation of fibroblast activation can lead to poor healing through excessive or insufficient cardiac scar formation (12, 23). In a proinflammatory environment driven by Ccl12, fibroblast activation is initiated at the proliferation step but does not continue to progress to the differentiated reparative myofibroblast phenotype. Having incompletely activated fibroblasts that are less responsive to apoptotic stimuli compared with myofibroblasts would set the stage for excessive continued fibroblast presence that would alter long-term homeostasis of the cardiac wound. Controlling myofibroblast activation and function in order to stimulate proper wound healing will attenuate adverse or excessive LV remodeling and preserve LV function after MI (12).

The human homologue of Ccl12, hMCP-1, is a regulator of macrophage chemotaxis and has been linked to diseases characterized by monocyte-rich infiltrates (40–42). In patients, hMCP-1 is an immune diagnostic biomarker in the pathogenesis of chronic PD (43). Both mCcl2 and mCcl12 are homologues of hMCP-1, with mCcl2 being 75% homologous (Bit Score = 114) and mCcl12 being 84% homologous (Bit score = 138) to the human form. The overlapping and distinct activities of mCcl2 and mCcl12 allow subcomponents of the hMCP-1 protein to be dissected. After MI, mCcl2 has been shown to regulate macrophage recruitment and activation (44, 45). In addition, cardiac myofibroblasts isolated from WT but not from Ccl2-deleted animals undergoing repetitive myocardial ischemia and reperfusion demonstrated enhanced proliferative capacity (45). Both mCcl2 and mCcl12, therefore, stimulate increased proliferation and decreased migration in cardiac fibroblasts. In addition, in vitro hMCP-1 and mCcl12 — but not mCcl2 — inhibited collagen and αSMA expression in human fetal lung fibroblasts, human pulmonary fibroblasts, and human preadipocytes (31, 45). While the mouse has two homologues of hMCP-1, the
mCcl12 homologue matches more closely to human Ccl2 than the mCcl2, both in terms of structure and function. Structurally, both human Ccl2 and mouse Ccl12 lack the β-strand that is present in the mCcl2, indicating that mCcl12 is structurally closer and, thus, better mimics hMCP-1.

The chemokine receptor Ccr2 is the only known receptor for Ccl12 (29). Ccr2i after MI attenuates LV remodeling by reducing inflammation through decreased macrophage recruitment (30, 46). Our study revealed Ccr2 plays a crucial role in LV remodeling by regulating fibroblast activation. Macrophage secretion of Ccl12 activated Ccr2 to inhibit myofibroblast activation and decrease ECM production. Unexpectedly, Ccl12 actions on fibroblast proliferation and migration were independent of Ccr2, consistent with reports that Ccl12 has unidentified receptors (29). Ccl12 interaction with these receptors may be responsible for stimulating a proliferative yet inflammatory fibroblast.

After MI, monocytes are recruited to the infarct in two phases. The first phase is dominated by Ly6chigh monocytes that give rise to early inflammatory macrophages, which remove necrotic tissue by phagocytosis and secrete proteolytic enzymes including MMP-2 (47). In the second phase, Ly6cdlow monocytes facilitate wound healing and regeneration to promote myofibroblast accumulation, collagen deposition, and angiogenesis (17, 47). Chronic inflammation induced by LPS exposure exacerbated LV adverse remodeling by accelerating macrophage infiltration and inhibiting resolution of M1 macrophages. The combined early removal of macrophages and decreased M2 activation provides a mechanism for impaired LV wound healing. Similar to what we observed, studies performed by both De Jesus et al. (Ripplinger lab) and Panizzi et al. (Nahrendorf lab) have shown that acute LPS exposure at the time of MI increases protease activity, phagocytic activity, macrophage infiltration, and LV dilation at d5 after MI (48, 49). In contrast, macrophages numbers were elevated at d5 after acute LPS exposure.

Figure 6. Macrophage secretion of Ccl12 regulates wound healing by decreasing myofibroblast activation and increasing proliferation. (A) Stimulating naive fibroblasts with macrophage conditioned media isolated from lipopolysaccharide-preexposed MI mice (LPS+MI) increased cell proliferation but had no effect on cell migration. n = 4/group (4M); 4.5 ± 0.1 months for all groups. (B) Fibroblasts stimulated with macrophage conditioned media from LPS+MI mice decreased gene levels of α-smooth muscle actin (αSMA), collagen I, and TGFβ1 and increased BrdU uptake to indicate increased fibroblasts proliferation. n = 6/group (4M); 4.0 ± 0.1 months for all groups. (C) Secretion of extracellular matrix (ECM) decreased in fibroblasts stimulated with macrophage media from LPS+MI mice as shown by decreased procollagen and fibronectin protein. Ccl12 blocking antibody (Ccl12i) attenuated the effect of the LPS+MI macrophage secretome. n = 6/group (6M); 4.0 ± 0.1 months for all groups. All in vitro stimulation experiments were paired. Data is shown as box and whisker plots with mean ± minimum/maximum; one-way ANOVA with Student Newman-Keuls post-test; *P < 0.05 vs. MI; †P < 0.05 vs. LPS+MI.
whereas, after chronic exposure, macrophage numbers are attenuated at the later phase after MI. In addition, acute LPS exposure increases cardiac fibrosis without the onset of cardiac injury, suggesting that the mechanisms behind LV dysfunction may have distinct signaling attributes that distinguish acute and chronic inflammation mechanisms (50).

In our clinical study, the post-MI patients were not assessed for PD; rather, plasma endotoxemia levels were measured. We reviewed the clinical data, and there were no indications of active infection. Only one patient was prescribed an antibiotic (as a preventative after coronary bypass surgery); of note, this patient was not part of the high-endotoxin group. Our clinical data demonstrate that chronic inflammation due to a low-grade infection can induce adverse remodeling. This is consistent with Ismahil et al., who showed that increased proinflammatory macrophages led to development of chronic heart failure (51). Additional studies evaluating whether the source of endotoxemia changes response are warranted.

In conclusion, chronic inflammation prolonged the post-MI proinflammatory macrophage response, which in turn attenuated myofibroblast activation and impaired cardiac wound healing to increase cardiac fibrosis.

Figure 7. Ccr2 activation by Ccl12 induced fibroblast dysfunction and impaired wound healing. (A) In vitro stimulation of cardiac fibroblasts with Ccl12 attenuated cell migration (by electric cell–substrate impedance sensing, ECIS) and increased cell proliferation (by BrdU uptake) independent of Ccr2. n = 5/group (SM); 4.5 ± 0.1 months for all groups. All in vitro stimulation experiments were paired. (B) Collagen I, fibronectin, TGFβ1, and α-smooth muscle actin (αSMA) significantly decreased in Ccl12-stimulated fibroblasts. Ccr2 inhibition partially restored Ccl12 effects on all ECM genes. n = 5/group (SM); 4.5 ± 0.1 months for all groups. All in vitro stimulation experiments were paired. (C) In vivo Ccl12 exposure in the post-MI LV increased cardiac rupture similar to rates observed for the LPS+MI mice. This was attenuated by administering a Ccl12 blocking antibody (Ccl12i) in vivo. (D) Administration of Ccl12i increased the 25 kDa band by 2-fold, indicating successful Ccl12 inhibition. (E) In addition, Ccl12 upregulation increased collagen turnover and (F) active MMP-2 similar to what was observed in LPS+MI mice. Ccl12i attenuated this effect. No change was observed in IgG controls. n = 4/group (2M, 2F for MI, IgG, and Ccl12i; 1M, 3F for recombinant Ccl12 [rCcl12]). MI = 4.7 ± 0.1 months; IgG = 3.6 ± 0.1 months; rCcl12 = 4.3 ± 0.2 months; Ccl12i = 3.6 ± 0.1 months. Data is shown as box and whisker plots with mean ± minimum/maximum; one-way ANOVA with Student Newman–Keuls post-test; *P < 0.05 vs. 0.1% FBS; †P < 0.05 vs. Ccl12 stimulated cells; ‡P < 0.05 vs. d7 MI.
rupture and dilation. Macrophage secretion of Ccl12 mediated these effects. These findings give us insight into the cellular events that increase the risk of mortality and heart failure in post-MI patients with a chronic inflammatory disease and provide global mechanisms whereby chronic inflammation impairs wound healing.

Methods

Supplemental Methods are available online with this article.

Experimental design. C57BL/6J WT mice, 3–7 months of age (4.6 ± 0.1 months) and equal male and female numbers, were obtained from Jackson Laboratories for this study. Groups were examined simultaneously in a random experimental design, with the evaluator blinded to groups for all data acquisition and analyses. Porphyromonas gingivalis LPS was infused by osmotic minipumps (models 2004 and 1007D, Durect) to induce chronic inflammation as described previously (11). After 28 days, MI was induced through permanent ligation of the left anterior descending coronary artery (LPS+MI). Mice were continually infused with LPS until tissue collection (11, 52). Recombinant Ccl12, Ccl12 blocking antibody, or goat IgG antibody were infused by osmotic pump at the time of MI surgery to dissect Ccl12 mechanisms on cardiac wound healing in vivo.

Coronary artery ligation. Coronary artery ligation was performed as described previously (11, 53). Mice were anesthetized with 1%–2% isoflurane in oxygen, intubated, and put on a standard rodent ventilator. An 8-0 suture was used to ligate the left coronary artery, and MI was confirmed by LV blanching and ECG changes showing ST segment elevation. Prior to the surgery, buprenorphine (0.1 mg/kg, UMMC Pharmacy) was administered.

Macrophage and fibroblast phenotyping. To test the effect of periodontal-induced chronic inflammation, genetic markers were used to assess cell phenotype, as shown in Supplemental Tables 1 and 2.
Protein alignment and structure analyses. Alignment of human MCP-1 (UniProt, P13500), mouse Ccl2 (UniProt, P10148), and mouse Ccl12 (UniProt, Q62401) was performed using Basic Local Alignment Search Tool (BLAST) and Constraint-based Multiple Alignment Tool (COBALT) as previously described (54–56). Structural 3D models were built using SWISS-MODEL Workspace (57–59).

Human subjects. Plasma was collected 22 ± 12 hours (range of 4–66 hours) after hospitalization in post-MI patients (n = 97; age, median 58 years and range 33–86 years; 38% women; 48% African American). Patient characteristics are listed in Table 2. Echocardiographic data was collected within 20 ± 14 hours after admission. Plasma LPS levels were detected and semiquantified by a chromogenic assay (Endpoint Chromogenic LAL Assay, Lonza). EU/ml were calculated by a standard curve and best-fit linear trend line. No patient had septic levels of endotoxin.

Statistics. Multiple group comparisons were analyzed by one-way ANOVA, followed by the Student Newman-Keuls when the Bartlett’s variation test passed, or by the nonparametric Kruskal-Wallis ANOVA.

Table 2. Post-MI patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>0–1 EU/ml n = 84</th>
<th>&gt;1 EU/ml n = 13</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>58 ± 13</td>
<td>57 ± 8</td>
<td>0.86</td>
</tr>
<tr>
<td>Sex (male/female; % female)</td>
<td>53/31 (37%)</td>
<td>8/5 (38%)</td>
<td>0.92</td>
</tr>
<tr>
<td>Plasma collection time (h)</td>
<td>22 ± 12</td>
<td>23 ± 12</td>
<td>0.68</td>
</tr>
<tr>
<td>Body mass index</td>
<td>30 ± 7</td>
<td>32 ± 9</td>
<td>0.42</td>
</tr>
<tr>
<td>Race (white/African American; % AA)</td>
<td>45/39 (46%)</td>
<td>6/7 (54%)</td>
<td>0.62</td>
</tr>
<tr>
<td>Diabetes history (no. of patients)</td>
<td>29 (37%)</td>
<td>5 (38%)</td>
<td>0.96</td>
</tr>
<tr>
<td>Previous MI (no. of patients)</td>
<td>14 (17%)</td>
<td>1 (8%)</td>
<td>0.39</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>128 ± 22</td>
<td>137 ± 29</td>
<td>0.21</td>
</tr>
<tr>
<td>Peak troponin (ng/ml)</td>
<td>2.8 ± 3.6</td>
<td>2.6 ± 2.9</td>
<td>0.90</td>
</tr>
<tr>
<td>Monocyte chemotactic protein-1 (pg/ml)</td>
<td>293 ± 254</td>
<td>492 ± 372</td>
<td>0.02</td>
</tr>
<tr>
<td>End diastolic diameter (cm)</td>
<td>4.63 ± 0.68</td>
<td>5.33 ± 1.04</td>
<td>0.002</td>
</tr>
<tr>
<td>End systolic diameter (cm)</td>
<td>3.40 ± 0.67</td>
<td>4.15 ± 1.25</td>
<td>0.003</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>46 ± 14</td>
<td>41 ± 14</td>
<td>0.25</td>
</tr>
</tbody>
</table>

Data are mean ± SD.
test followed by Dunn post-hoc test when normal distribution of data was not met. For two group comparisons, the nonparametric Wilcoxon rank sum test was used. The survival rate was analyzed by Kaplan–Meier survival analysis and compared by the log-rank test. Rupture rates were analyzed by Fisher’s exact test. A value of $P < 0.05$ was considered statistically significant. The heat map and volcano plot were constructed using statistical software available in Metaboanalyst 3.0 (www.metaboanalyst.ca/) (60, 61). The top features were ranked by two-tailed $t$ tests to retain the most contrasting patterns. Power analysis was performed to ensure all experiments were sufficiently powered to assess changes.

**Study approval.** This study complies with the Declaration of Helsinki (62). All animal procedures were approved by the IACUC at the University of Mississippi Medical Center in accordance with the Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011) and followed the ARRIVE guidelines (63). Written informed consent was collected from all patients under protocols approved by the ethics committee of the University of Mississippi Medical Center (IRB protocol 2013-0164).

**Author contributions**
KYDP and MLL conceived the hypothesis. KYDP analyzed all data and performed mouse surgeries, echocardiography, and flow cytometry; CAC, ERF, and KYDP performed cell culture; CAC, DS, MJ, and KYDP performed immunofluorescence; ERF, PLC, and KYDP performed immunoblotting; ERF performed MMP-12 dot blots; KYDP and PLC performed gene analysis; MEH, KYDP, and OKE analyzed patient characteristics; and KYDP, RPI, YM, MRG, WB, MEH, and MLL designed experimental procedures, interpreted data, and drafted manuscript. All authors read, edited, and approved the final manuscript.

**Acknowledgments**
This work was supported by the American Heart Association (15SDG22930009 to YM), by the NIH (T32HL105324 to OKE and HL075360, HL129823, and GM114833 to MLL), by the Biomedical Laboratory Research and Development Service of the Department of Veterans Affairs (S10IBX000505 to MLL and IK2BX003922 to KYDP), and by NIH HL051971, GM103437, GM115428, GM103476, and GM103328. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association, the NIH, or the Veterans Administration.

Address correspondence to: Kristine Y. DeLeon-Pennell or Merry L. Lindsey, Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State Street, Jackson, Mississippi 39216-4505, USA. Phone: 601.815.0816; Email: kdeleon@umc.edu (K.Y. DeLeon-Pennell). Phone: 601.815.1329; Email: mllindsey@umc.edu (M.L. Lindsey).


50. Lew WY, Bayna E, Dalle Molle E, Contu R, Condorelli G, Tang T. Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in mice. PLoS ONE. 2014;9(9):e107556.